# US 2015/0306211 A1 · Process for producing an allergen extract

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0306211 A1
- Document ID: US20150306211A1
- Status: Published application
- Kind: A1
- Application number: 13/577,787
- Filed: 2011-02-11
- Published: 2015-10-29
- Earliest claimed: 2010-02-12
- Assignees: Laboratorios Leti, S.L.
- Inventors: Jeronimo CARNES SANCHEZ
- Web page: https://patentgrep.com/patent/US20150306211A1

## CPC

- A61K 39/35: Allergens
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/37: from fungi
- C07K 14/415: from plants
- C07K 14/435: from animals; from humans
- C07K 14/43531: {from mites}
- C07K 14/47: from mammals
- A61K 2039/577: {tolerising response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention discloses processes for producing native, depigmented and polymerised allergen extracts. The invention further discloses extracts produced via the processes, and pharmaceutical and vaccine compositions comprising the extracts, for diagnosis and treatment of allergy.

## Claims

### Claim 1

A process for producing an allergen extract comprising:
a) contacting a source material comprising with a liquid extraction agent to produce a mixture containing lipids dissolved in liquid phase and a solid phase consisting of source material residue comprising allergens and proteins,
b) subjecting the mixture to a first separation step to isolate the source material residue,
c) contacting the source material residue with an allergen extract agent to produce a mixture of allergens dissolved in liquid phase, and a solid phase consisting of non-allergenic residue,
d) subjecting the mixture to a second separation step to isolate the allergens dissolved in liquid phase, to produce a crude allergen extract,
e) subjecting the crude allergen extract to a low molecular fraction removal step to remove molecules having a molecular size of less than 3.5 kDa, and
f) carrying out step e) until the allergen extract has conductivity of below 1000 μS/cm at 3-5° C. to obtain a purified native allergen extract.

### Claim 2 (depends on 1)

The process as claimed in claim 1 wherein the low molecular fraction removal step is continued until the conductivity is less than 500 μS/cm at 3-5° C.

### Claim 3 (depends on 1)

The process as claimed in claim 1, further comprising a further treatment step, comprising:
g) acidifying the native allergen extract to pH 2 to 3.0 and maintaining the acidified extract for 5-30 minutes, followed by subjecting the extract to a low molecular fraction removal step to remove molecules having a molecular size of less than 3.5 kDa, and adjusting the pH to 7.0-8.0 to produce a depigmented allergen extract.

### Claim 4 (depends on 3)

The process as claimed in claim 3 wherein the native allergen extract is acidified to pH 2 to 2.1

### Claim 5 (depends on 3)

The process as claimed in claim 3 wherein the native allergen extract is acidified to pH 2.0 to 4.0.

### Claim 6 (depends on 1)

The process as claimed, in claim 1, further comprising a polymerisation step, comprising:
h), contacting a native allergen extract or a depigmented allergen extract with glutaraldehyde or formaldehyde,
i) subjecting the extract to a molecular fraction removal step to remove molecules having a molecular size of less than 100 kDa, and
j) carrying out step i) until the allergen extract has a conductivity of below 210 μS/cm at 3-5° C. and/or is absent of glutaraldehyde as determined by UV or visible scanning, to obtain a polymerised allergen extract or a depigmented polymerised allergen extract.

### Claim 7 (depends on 1)

A native allergen extract obtainable according to the process of claim 1.

### Claim 8 (depends on 3)

A depigmented allergen extract obtainable according to the process of claim 3.

### Claim 9 (depends on 5)

A depigmented polymerised allergen extract obtainable according to the process of claim 5.

### Claim 10 (depends on 6)

An allergen extract according to claim 6 wherein the source material is selected from including food allergens, peanuts, whole peanuts, air-borne allergens (e.g. pollen (tree pollen, weed pollen, grass pollen, cereal pollen)), dust mites, fungi, moulds), mites, grasses, tree and weed allergens, epithelial allergens (animal hair, animal dander, e.g. cat hair and dander and dog hair and dander) and insect allergens (e.g. cockroach, fleas, bee and wasp venom).

### Claim 11 (depends on 9)

The allergen extract according to claim 9 wherein the source material is selected from food allergens (Arachis hypogeal), pollen (Alnus glutinosa, Betula alba, Corylus avellana, Cupressus arizonica, Olea europea, Platanus sp, Cynodon dactylon, Dactylis glomerata, Festuca elatior, Holcus lanatus, Lolium perenne, Phleum pratense, Phragmites communis, Poa pratensis, Ambrosia elatior, Artemisia vulgaris, Chenopodium album, Parietaria judaica, Plantago lanceolata, Salsola kali, Avena sativa, Hordeum vulgare, Secale cereal, Triticum aestivum, Zea mays), dust mites (Acarus siro, Blomia tropicalis, Dermatophagoides farinae, Dermatophagoides microceras, Dermatophagoidespteronyssinus, Euroglyphus maynei, lepidoglyphus destructor, Tyrophagus putrescentiae), fungi and moulds (Alternaria alternate, Cladosporium herbarum, Aspergillusfumigatus), epithelial allergens (cat hair and dander, dog hair and dander, horse hair and dander, human hair and dander, rabbit hair and dander, and feathers), insect allergens (ant, flea, mites, cockroach, wasp venom and bee venom).

### Claim 12 (depends on 9)

The allergen extract of claim 9 wherein the source material is selected from peanut (Arachis hypogea), pollen (Olea europaea, Parietaria judaica, Phragmites communis and Phleum pratense), mites (Dermatophagoides pteronyssinus), and epithelial (cat dander).

### Claim 13 (depends on 12)

The allergen extract of claim 12 wherein the source material is Arachis hypogea.

### Claim 14 (depends on 6)

The allergen extract according to claim 6 for the use in the treatment of allergy.

### Claim 15 (depends on 13)

Use of an allergen extract of claim 13 in the treatment of peanut allergy.

### Claim 16 (depends on 12)

A pharmaceutical composition comprising an allergen extract according to claim 12.

### Claim 17 (depends on 6)

A vaccine comprising an allergen extract according to claim 6.
